Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

776.38
8,254,426

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RSPH

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?

by Zacks Equity Research

Sector ETF report for RSPH

NVS or LLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?

Pfizer (PFE) Stock Down on Halting Development of Obesity Drug

by Zacks Equity Research

Shares of Pfizer's (PFE) fell 3.7% on Monday after management's decision to terminate the development of an experimental obesity pill following concerns over liver safety.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $458.84, moving +0.25% from the previous trading session.

Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs

by Zacks Equity Research

Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.

Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More

by Zacks Equity Research

Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.

DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly

by Zacks Equity Research

DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.

Sweta Killa headshot

ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics

by Sweta Killa

Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.

Company News for Jun 21, 2023

by Zacks Equity Research

Companies in The News Are: DICE,LLY,XOM,LEN,DHI

Alexandria (ARE) Divests 5 Non-Core Properties for $365M

by Zacks Equity Research

Keeping up with its capital-recycling strategy, Alexandria (ARE) announces the disposition of five non-core assets in Greater Boston, spanning 428,663 rentable square feet, for $365 million.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Verve (VERV) Up 9.9% in a Week on Collaboration With Eli Lilly

by Zacks Equity Research

Verve's (VERV) shares rise on collaboration with Eli Lilly to develop gene editing treatment for cardiovascular disease.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Lilly's (LLY) Migraine Drug Fails Vis-a-Vis Pfizer's Nurtec ODT

by Zacks Equity Research

Results from a post-approval study show that treatment with Lilly's (LLY) Emgality failed to achieve statistical superiority over Pfizer's Nurtec ODT in preventing episodic migraine in adults.

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $453.93 in the latest trading session, marking a +1.39% move from the prior day.

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights Apple, UnitedHealth, Eli Lilly, Walmart and Becton, Dickinson

by Zacks Equity Research

Apple, UnitedHealth, Eli Lilly, Walmart and Becton, Dickinson are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Apple, UnitedHealth & Eli Lilly

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), UnitedHealth Group Incorporated (UNH) and Eli Lilly and Company (LLY).

Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement

by Zacks Equity Research

An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Eli Lilly (LLY) closed at $446.04, marking a +0.09% move from the previous day.

Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod

by Zacks Equity Research

Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.

Ethan Feller headshot

Buy These 3 Top-Ranked ETFs and Never Sell

by Ethan Feller

ETFs provide instant diversification by pooling together a basket of securities across various sectors, industries, or asset classes

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.